首页> 外文期刊>臨床血液 >Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia
【24h】

Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia

机译:在同一供体中的第二种移植在没有调理的非骨髓造血干细胞移植治疗慢性骨髓白血病后

获取原文
获取原文并翻译 | 示例
           

摘要

We describe a 56-year-old woman with chronic myeloid leukemia (CML) and a past history of stroke, who underwent nonmyeloablative hematopoietic stem cell transplantation (NST) with conditioning consisting of fludarabine and cyclophosphamide. The regimen related toxicity was minimal and patient did not require transfusions of any blood products nor did she have any infections after the NST Since mixed chimerism was observed in both lymphocytes (70% were donor type) and granulocytes (none were donor type) at 56 days after NST, donor lymphocyte infusion (DLI) was performed on day 68 and then immunosuppressant therapy was discontinued. DLI resulted in graft versus leukemia (GVL) effect, causing pancytopenia and bone marrow aplasia. A second hematopoietic stem cell transplantation was performed without conditioning on day 157, and complete donor type hematopoiesis and molecular remission of CML were achieved. Although engraftment of donor hematopoietic stem cells was not obtained after the first transplantation, donor lymphocytes were engrafted by nonmyeloablative conditioning and immunosuppression. That is, the same result might have been achieved even if the patient had received transfusion of only donor lymphocyte subsets in the first step. Based on this case report, a potential cell therapy is proposed composed of the preceding donor lymphocyte infusion alone, which induces GVL effects, and subsequent donor hematopoietic stem cell transplantation.
机译:我们描述了一名慢性骨髓白血病(CML)的56岁女性,以及过去的卒中史,人们接受了非柔化的造血干细胞移植(NST),其调理由氟氮胺和环磷酰胺组成。方案相关的毒性是最小的,患者不需要任何血液制品输血,而且由于在淋巴细胞(70%是供体类型)和颗粒细胞(无造粒剂)在56时观察到混合斜切位后,她在NST中有任何感染NST后的天数,供体淋巴细胞输注(DLI)在第68天进行,然后停止免疫抑制治疗。 DLI导致移植物与白血病(GVL)效应,导致韧皮细胞增生和骨髓患者。在第157天不调理的情况下进行第二次造血干细胞移植,并达到完全供体型血小杂物和CML的分子缓解。尽管在第一移植后未获得供体造血干细胞的植入,但是通过非粘合调理和免疫抑制植入供体淋巴细胞。也就是说,即使患者在第一步中仅接受仅受供体淋巴细胞亚群的输血的输血,也可以实现相同的结果。基于这种情况报告,提出了一种单独的供体淋巴细胞输注组成的潜在细胞疗法,其诱导GVL效应,随后的供体造血干细胞移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号